Source: International Congress 2017 – Chinese Programme 2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Joos (Ghent, Belgium). Severe asthma: from inflammatory phenotype to treatment. International Congress 2017 – Chinese Programme 2017

Member's Comments

No comment yet.

Related content which might interest you: Markers of severity and inflammatory profile during exacerbations of severe asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Conclusion: clinical phenotypes of asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Severe asthma: classification and treatment Source: Virtual Congress 2021 – Clinical year in review Year: 2021 Inflammatory phenotypes of severe exacerbation of COPD, a clinico-laboratory characterization. Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma Source: International Congress 2016 – Airway biomarkers Year: 2016 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Characteristics, definition and phenotypes of severe asthma Source: Eur Respir Mon 2011; 51: 50-58 Year: 2011 Inflammatory markers of atherogenesis in patients with uncontrolled severe asthma Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Severe asthma: one disease many definitions Source: International Congress 2019 – Asthma and the world Year: 2019 Severe asthma: approach to diagnosis and treatment Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond Year: 2008 Eosinophilic refractory inflammation in OCS-dependent severe asthma Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Pathophysiology of severe asthma phenotypes Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 Severe pulmonary hypertension in lung disease: phenotypes and response to treatment Source: Eur Respir J 2015; 46: 1378-1389 Year: 2015 Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 Treatment: how does inflammatory phenotype influence response to treatment in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 Eosinophilic inflammation amplifies the prednisolone-induced prothrombotic state in asthma Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Lymphoid follicles in (very) severe COPD: beneficial or harmful? Source: Eur Respir J 2009; 34: 219-230 Year: 2009 Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016